Pharmacokinetics of factor VIII and factor IX

Haemophilia

Volumn 9, Issue SUPPL. 1, 2003, Pages 94-100

  Morfini, Massimo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Factor IX; Factor VIII; Haemophilia; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CHROMOGENIC SUBSTRATE; PRECONATIVE HT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIBOSOME DNA;

ACCURACY; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING TEST; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; HEMOPHILIA; HEMOSTASIS; HUMAN; INDIVIDUALIZATION; LABORATORY TEST; MEDICAL SOCIETY; PREDICTION; PRIORITY JOURNAL; STANDARDIZATION; THROMBOSIS;

EID: 0037764676     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.9.s1.8.x     Document Type: Article

References (40)

1. Kjellman H. Calculations of factor VIII in vivo recovery and half life. Scand J Haematol 1984; 33 (Suppl. 40): 165-84.
2. Matucci M, Longo G, Morfini M et al. Pharmacokinetics of factor VIII. C. Appropriateness of the one-compartment model for estimating clearance. Il Farmaco 1983; 38: 306-11.
3. Matucci M, Messori A, Donati-Cori G et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985; 34: 22-8.
4. Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thromb Res 1986; 42: 471-6.
5. Morfini M, Grasela TH, Longo G et al. Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients. Haematologica 1985; 70: 454-6.
6. Messori A, Longo G, Matucci M, Morfini M, Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
7. Messori A, Longo G, Morfini M et al. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988; 35: 663-8.
8. Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-95.
9. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73.
10. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
11. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
12. Lee M, Morfini M, Schulman S, Ingerslev J. The design and analysis of pharmacokinetic studies of coagulation factors. Factor VIII/IX SSC-ISTH recommendations at http://www.med.unc.edu/isth/fviiipharmaco.htm.
13. Committee for Proprietary Medicinal Products. Guidance on the Clinical Investigation of Human Plasma Derived Factor VIII and IX Products. London: CPMP, 19 October 2000.
14. Messori A, Bosi A, Guidi S et al. A pharmacokinetic program for least-squares and Bayesian analysis of repeated-dose pharmacokinetic curves. Comp Meth Progr Biomed 1992; 38: 27-35.
15. Nilsson IM, Hedner U. Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br J Haematol 1977; 37: 543-57.
16. Prowse CV. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards uses for potency assignment. Thromb Haemost 1995; 74: 1191-6.
17. Messori A, Morfini M, Blomback M et al. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicentre assays of factor VIII activity. Thromb Res 1992; 65: 699-708.
18. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800-5.
19. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.
20. Fijnvandraat K, Berntorp E, ten Cate JW et al. Recombinant, b-domain deleted Factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
21. Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995; 35: 319-23.
22. Messori A, Nilsson IM, Rossi Ferrini P. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb Res 1993; 71: 175-84.
23. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
24. Morfini M, Mannucci PM, Longo G, Cinotti S, Messori A. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. Thromb Res 1991; 61: 285-90.
25. Morfini M, Cinotti S, Paladino E, Mannucci PM, Bellatreccia A, Bianchi C. Single dose pharmacokinetic evaluation of ReFacto, B-domain-deleted recombinant factor VIII, using one-stage and chromogenic assays: comparison between plasma and concentrate laboratory standards. Abstract at the 42nd Annual Meeting of the ASH, December 1-5, 2000: San Francisco, CA. Blood 2000; 96: 490.
26. Longo G, Messori A, Morfini M et al. Evaluation of factor VIII pharmacokinetics in hemophilia A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol 1989; 30: 140-9.
27. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol/Oncol 1994; 1: 471-8.
28. Messori A, Longo G, Morfini M et al. Individualization of Factor VIII dosage. J Clin Hosp Pharm 1984; 9: 95-103.
29. Ruffo S, Messori A, Grasela TH et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed 1985; 19: 167-77.
30. Kirkwood TBL, Barrowcliffe TW. Discrepancies between one-stage and two-stage assay of Factor VIII. C. Br J Haematol 1978; 40: 333-8.
31. Barrowcliffe TW, Watton J, Harmon A, Tubbs JF, Kemball-Cook G. Potency of high purity factor VIII concentrates. Lancet 1990; 336: 124.
32. Kemball-Cook G, Tubbs JE, Dawson NJ, Barrowcliffe TW. The behaviour of different factor VIII concentrates in a chromogenic factor X-activating system. Br J Haematol 1993; 84: 273-8.
33. Niemetz J, Nossel HL. Activated coagulation factors. In vivo and in-vitro studies. Br J Haematol 1969; 16: 337-51.
34. Mikaelsson M, Oswaldsson U, Nilsson IM. Potency and in vivo recovery of high purity factor VIII concentrates. Thromb Haemost 1994; 72: 160-1.
35. Barrowcliffe TW. Standardization and assay. Semin Thromb Hemost 1993; 19: 73-9.
36. Barrowcliffe TW, Raut S, Hubbard R. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 634-40.
37. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
38. Lee C, Owens D, Bray G et al. Pharmacokinetics of recombinant factor VIIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
39. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
40. Ingerslev J, Oswaldsson U, Renlund S, Mikaelsson M and the Nordic ReFacto Study Group. Results of a collaborative Nordic field Study (RASPUTIN) on determination of recombinant B-domain deleted Factor VIII in Plasma employing a (Refacto) concentrate standard. Abstract P2576 at XVIII Congress of ISTH, July 6-12, 2001: Paris. Thromb Haemost (Suppl.) July 2001.